|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Defining Surgical Quality in Gastric Cancer: A RAND/UCLA Appropriateness Study显示文摘 | Savtaj Brar Calvin Law Robin McLeod Lucy Helyer Carol Swallow Lawrence Paszat Rajini Seevaratnam Roberta Cardoso Matthew Dixon Alyson Mahar Laercio G. Lourenco Lavanya Yohanathan Alina Bocicariu Tanios Bekaii-Saab Ian Chau Neal Church Daniel Coit Christop | 2013 | Journal of the American College of Surgeons2013，，2： | 3 |
| 2 | The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial显示文摘 | Colin Baigent Martin J Landray Christina Reith Jonathan Emberson David C Wheeler Charles Tomson Christoph Wanner Vera Krane Alan Cass Jonathan Craig Bruce Neal Lixin Jiang Lai Seong Hooi Adeera Levin Lawrence Agodoa Mike Gaziano Bertram Kasiske Robert Wal | 2011 | The Lancet2011，，9784： | 1 |
| 3 | Predictors of Clinical Course, Coronary Anatomy and Left Ventricular Function After Recovery From Acute Myocardial Infarction显示文摘 | GEORGE J. TAYLOR J. O?NEAL HUMPHRIES E. DAVID MELLITS BERTRAM PITT ROBERT A. SCHULZE LAWRENCE S.C. GRIFFITH STEPHEN C. ACHUFF | 1980 | Circulation1980，，5： | 1 |
| 4 | Experimental investigation of a two-phase ejector cycle suitable for use with low-pressure refrigerants R134a and R1234yf显示文摘 | Neal Lawrence Stefan Elbel | 2013 | International Journal of Refrigeration2013，，： | 1 |
| 5 | Experimental investigation of a two - phase ejectorcycle suitable for use with low - pressure refrigerants R134a and R1234yf显示文摘 | Neal Lawrence Stefan Elbel | 2014 | Interna- tional Journal of Refrigeration2014，，38： | 1 |
| 6 | Malignant Ascites: Clinical and Experimental Observations显示文摘 | R. NEAL GARRISON LAWRENCE D. KAELIN LOUIS S. HEUSER REBECCA H. GALLOWAY | 1986 | Annals of Surgery1986，，6： | 1 |
| 7 | Sun Exposure as a Risk Factor for Nuclear Cataract显示文摘 | Rachel E. Neale Jennifer L. Purdie Lawrence W. Hirst Adèle C. Green | 2003 | Epidemiology2003，，6： | 1 |
| 8 | Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus显示文摘AIM: To determine the safety profile of new hepatitis C virus(HCV) treatments in liver transplant(LT) recipients with recurrent HCV infection.METHODS: Forty-two patients were identified with recurrent HCV infection that underwent LT at least 12 mo prior to initiating treatment with a Sofosbuvir-based regimen during December 2013-June 2014. Cases were patients who experienced hepatic decompensation and/or serious adverse events(SAE) during or within one month of completing treatment. Controls had no evidence of hepatic decompensation and/or SAE. HIVinfected patients were excluded. Cumulative incidence of decompensation/SAE was calculated using the Kaplan Meier method. Exact logistic regression analysis was used to identify factors associated with the composite outcome. RESULTS: Median age of the 42 patients was 60 years [Interquartile Range(IQR): 56-65 years], 33%(14/42) were female, 21%(9/42) were Hispanic, and 9%(4/42) were Black. The median time from transplant to treatment initiation was 5.4 years(IQR: 2.1-8.8 years). Thirteen patients experienced one or more episodes of hepatic decompensation and/or SAE. Anemia requiring transfusion, the most common event, occurred in 62%(8/13) patients, while 54%(7/13) decompensated. The cumulative incidence of hepatic decompensation/SAE was 31%(95%CI: 16%-41%). Risk factors for decompensation/SAE included lower pre-treatment hemoglobin(OR = 0.61 per g/d L, 95%CI: 0.40-0.88, P < 0.01), estimated glomerular filtration rate(OR = 0.95 per m L/min per 1.73 m^2, 95%CI: 0.90-0.99, P = 0.01), and higher baseline serum total bilirubin(OR = 2.43 per mg/d L, 95%CI: 1.17-8.65, P < 0.01). The sustained virological response rate for the cohort of 42 patients was 45%, while it was 31% for cases.CONCLUSION: Sofosbuvir/ribavirin will continue to be used in the post-transplant population, including those with HCV genotypes 2 and 3. Management of anemia remains an important clinical challenge. | Neal Patel Kian Bichoupan Lawrence Ku Rachana Yalamanchili Alyson Harty Donald Gardenier Michel Ng David Motamed Viktoriya Khaitova Nancy Bach Charissa Chang Priya Grewal Meena Bansal Ritu Agarwal Lawrence Liu Gene Im Jennifer Leong Leona Kim-Schluger Joseph Odin Jawad Ahmad Scott Friedman Douglas Dieterich Thomas Schiano Ponni Perumalswami Andrea Branch | 2016 | World Journal of Gastroenterology2016，22，9： | 1 |
| 9 | Malignant Ascites: Clinical and Experimental Observations显示文摘 | R. NEAL GARRISON LAWRENCE D. KAELIN LOUIS S. HEUSER REBECCA H. GALLOWAY | 1986 | Annals of Surgery1986，，6： | 1 |
| 10 | Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results显示文摘AIM To assess the real-world effectiveness and cost of simeprevir(SMV), and/or sofosbuvir(SOF)-based therapy for chronic hepatitis C virus(HCV) infection.METHODS The real-world performance of patients treated with SMV/SOF ± ribavirin(RBV), SOF/RBV, and SOF/RBV with pegylated-interferon(PEG) were analyzed in a consecutive series of 508 patients with chronic HCV infection treated at a single academic medical center. Patients with genotypes 1 through 4 were included. Rates of sustained virological response-the absence of a detectable serum HCV RNA 12 wk after the end of treatment [sustained virological response(SVR) 12]-were calculated on an intention-to-treat basis. Costs were calculated from the payer's perspective using Medicare/Medicaid fees and Redbook Wholesale Acquisition Costs. Patient-related factors associated with SVR12 were identified using multivariable logistic regression.RESULTS SVR 12 rates were as follows: 86%(95%CI: 80%-91%)among 178 patients on SMV/SOF ± RBV; 62%(95%CI: 55%-68%) among 234 patients on SOF/RBV; and 78%(95%CI: 68%-86%) among 96 patients on SOF/PEG/RBV. Mean costs-per-SVR 12 were $174442(standard deviation: ± $18588) for SMV/SOF ± RBV; $223003(± $77946) for SOF/RBV; and $126496(± $31052) for SOF/PEG/RBV. Among patients on SMV/SOF ± RBV, SVR12 was less likely in patients previously treated with a protease inhibitor [odds ratio(OR): 0.20, 95%CI: 0.06-0.56]. Higher bilirubin(OR: 0.47, 95%CI: 0.30-0.69) reduced the likelihood of SVR12 among patients on SOF/RBV, while FIB-4 score ≥ 3.25 reduced the likelihood of SVR 12(OR: 0.18, 95%CI: 0.05-0.59) among those on SOF/PEG/RBV. CONCLUSION SVR 12 rates for SMV and/or SOF-based regimens in a diverse real-world population are comparable to those in clinical trials. Treatment failure accounts for 27% of costs. | Kian Bichoupan Neeta Tandon James F Crismale Joshua Hartman David Del Bello Neal Patel Sweta Chekuri Alyson Harty Michel Ng Keith M Sigel Meena B Bansal Priya Grewal Charissa Y Chang Jennifer Leong Gene Y Im Lawrence U Liu Joseph A Odin Nancy Bach Scott L Friedman Thomas D Schiano Ponni V Perumalswami Douglas T Dieterich Andrea D Branch | 2017 | World Journal of Virology2017，6，4： | 1 |
| 11 | The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial显示文摘 | Colin Baigent Martin J Landray Christina Reith Jonathan Emberson David C Wheeler Charles Tomson Christoph Wanner Vera Krane Alan Cass Jonathan Craig Bruce Neal Lixin Jiang Lai Seong Hooi Adeera Levin Lawrence Agodoa Mike Gaziano Bertram Kasiske Robert Wal | 2011 | The Lancet2011，，9784： | 1 |
| 12 | Optimal Management of Gastric Cancer: Results From an International RAND/UCLA Expert Panel显示文摘 | Natalie Coburn Rajini Seevaratnam Lawrence Paszat Lucy Helyer Calvin Law Carol Swallow Roberta Cardosa Alyson Mahar Laercio Gomes Lourenco Matthew Dixon Tanios Bekaii-Saab Ian Chau Neal Church Daniel Coit Christopher H. Crane Craig Earle Paul Mansfield No | 2014 | Annals of Surgery2014，，1： | 1 |
| 13 | Factors associated with success of telaprevir-and boceprevir-based triple therapy for hepatitis C virus infection显示文摘AIM To evaluate new therapies for hepatitis C virus(HCV), data about real-world outcomes are needed.METHODS Outcomes of 223 patients with genotype 1 HCV who started telaprevir-or boceprevir-based triple therapy(May 2011-March 2012) at the Mount Sinai Medical Center were analyzed. Human immunodeficiency viruspositive patients and patients who received a liver transplant were excluded. Factors associated with sustained virological response(SVR24) and relapse were analyzed by univariable and multivariable logistic regression as well as classification and regression trees. Fast virological response(FVR) was defined as undetectable HCV RNA at week-4(telaprevir) or week-8(boceprevir). RESULTS The median age was 57 years, 18% were black, 44% had advanced fibrosis/cirrhosis(FIB-4 ≥ 3.25). Only 42%(94/223) of patients achieved SVR24 on an intention-totreat basis. In a model that included platelets, SVR24 was associated with white race [odds ratio(OR) = 5.92, 95% confidence interval(CI): 2.34-14.96], HCV sub-genotype 1b(OR = 2.81, 95%CI: 1.45-5.44), platelet count(OR = 1.10, per x 104 cells/μL, 95%CI: 1.05-1.16), and IL28 B CC genotype(OR = 3.54, 95%CI: 1.19-10.53). Platelet counts > 135 x 103/μL were the strongest predictor of SVR by classification and regression tree. Relapse occurred in 25%(27/104) of patients with an end-oftreatment response and was associated with non-FVR(OR = 4.77, 95%CI: 1.68-13.56), HCV sub-genotype 1a(OR = 5.20; 95%CI: 1.40-18.97), and FIB-4 ≥ 3.25(OR = 2.77; 95%CI: 1.07-7.22). CONCLUSION The SVR rate was 42% with telaprevir-or boceprevirbased triple therapy in real-world practice. Low platelets and advanced fibrosis were associated with treatment failure and relapse. | Kian Bichoupan Neeta Tandon Valerie Martel-Laferriere Neal M Patel David Sachs Michel Ng Emily A Schonfeld Alexis Pappas James Crismale Alicia Stivala Viktoriya Khaitova Donald Gardenier Michael Linderman William Olson Ponni V Perumalswami Thomas D Schiano Joseph A Odin Lawrence U Liu Douglas T Dieterich Andrea D Branch | 2017 | World Journal of Hepatology2017，9，11： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员